All In Biotech

Drug Trial Radar · NCT06955104

Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

Last checked: Nov 19, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 145 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

145

Actual

Start

Apr 3, 2025

Primary completion

Jul 30, 2025

Study completion Jul 30, 2025

Sponsor

Lead sponsor
JW PharmaceuticalIndustry
Sponsor type
Industry
First posted
May 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients with Dyslipidemia

Conditions

  • Dyslipidemia

Interventions

  • JW0108 + C2407Drug

    JW0108 + C2407

  • JW0108 + C2407 placeboDrug

    JW0108 + C2407 placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in LDL-CTime frame: Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.